Global Anticoagulant Registry in the Field (GARFIELD-AF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01090362

Recruitment Status : Completed

First Posted : March 19, 2010

Last Update Posted : April 28, 2021

Sponsor:

Collaborators:

Bayer

University of Birmingham

Brigham and Women's Hospital

Quintiles, Inc.

Advanced Drug and Device Services SAS

Apothecaries Clinical Research

Information provided by (Responsible Party):

Thrombosis Research Institute

Study Description

Brief Summary:

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is a non-interventional, observational study that characterized a global population of non-valvular atrial fibrillation patients. The registry was used to document global baseline characteristics, current treatment strategies and outcome measures. Characterisation of a number of AF sub-populations was also completed. GARFIELD-AF is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).

Condition or disease
Atrial Fibrillation

Detailed Description:

Using data from more than 1000 randomly selected centres across 35 countries, representing all possible care settings, the registry will help to characterize real-life anticoagulant treatment patterns and outcomes, including rates of stroke and bleeding complications, as well as provide data on other important issues, such as physicians' compliance with guidelines and patients' adherence to therapy. This is particularly timely as standard practice moves away from vitamin K antagonist (VKA)-dominated therapy and towards a new era of novel oral anticoagulants (OACs), i.e. direct Factor Xa inhibitors and direct thrombin inhibitors.

To ensure a dataset that truly reflects current practice, the investigators are requested to prospectively enrol all newly diagnosed patients with non-valvular AF who have at least one additional investigator-determined risk factor for stroke. Patients are consecutively recruited into one of five cohorts and followed up for at least 2 years.

Study Design

Layout table for study information

Study Type :	Observational
Actual Enrollment :	57250 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation.
Actual Study Start Date :	December 21, 2009
Actual Primary Completion Date :	June 16, 2019
Actual Study Completion Date :	May 18, 2020

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Familial atrial fibrillation

MedlinePlus related topics: Atrial Fibrillation Blood Thinners

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
Cohort 1 Cohort complete with 5,088 retrospective patients and 5,499 prospective patients recruited from 19 countries.
Cohort 2 Cohort completed with 11,351 patients enrolled from 30 countries
Cohort 3 Cohort 3 completed with 11,139 patients enrolled globally from 32 countries
Cohort 4 Cohort 4 completed with 11,2780 patients enrolled from 35 countries.
Cohort 5 Final cohort completed with 12,186 patients enrolled.

Outcome Measures

Primary Outcome Measures :

Death [ Time Frame: 4 months ]
All cause mortality including cardiovascular and non-cardiovascular death
Death [ Time Frame: 8 months ]
All cause mortality including cardiovascular and non-cardiovascular death
Death [ Time Frame: 12 months ]
All cause mortality including cardiovascular and non-cardiovascular death
Death [ Time Frame: 16 months ]
All cause mortality including cardiovascular and non-cardiovascular death
Death [ Time Frame: 20 months ]
All cause mortality including cardiovascular and non-cardiovascular death
Death [ Time Frame: 24 months ]
All cause mortality including cardiovascular and non-cardiovascular death
Death [ Time Frame: 3 years ]
All cause mortality including cardiovascular and non-cardiovascular death
Death [ Time Frame: 4 years ]
All cause mortality including cardiovascular and non-cardiovascular death
Stroke/Systemic embolism (SE) [ Time Frame: 4 months ]
Stroke/SE was defined as the combined end points of ischemic stroke, and SE
Stroke/Systemic embolism (SE) [ Time Frame: 8 months ]
Stroke/SE was defined as the combined end points of ischemic stroke, and SE
Stroke/Systemic embolism (SE) [ Time Frame: 12 months ]
Stroke/SE was defined as the combined end points of ischemic stroke, and SE
Stroke/Systemic embolism (SE) [ Time Frame: 16 months ]
Stroke/SE was defined as the combined end points of ischemic stroke, and SE
Stroke/Systemic embolism (SE) [ Time Frame: 20 months ]
Stroke/SE was defined as the combined end points of ischemic stroke, and SE
Stroke/Systemic embolism (SE) [ Time Frame: 24 months ]
Stroke/SE was defined as the combined end points of ischemic stroke, and SE
Stroke/Systemic embolism (SE) [ Time Frame: 3 years ]
Stroke/SE was defined as the combined end points of ischemic stroke, and SE
Stroke/Systemic embolism (SE) [ Time Frame: 4 years ]
Stroke/SE was defined as the combined end points of ischemic stroke, and SE
Major bleeding [ Time Frame: 4 months ]
Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.
Major bleeding [ Time Frame: 8 months ]
Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.
Major bleeding [ Time Frame: 12 months ]
Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.
Major bleeding [ Time Frame: 16 months ]
Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.
Major bleeding [ Time Frame: 20 months ]
Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.
Major bleeding [ Time Frame: 24 months ]
Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.
Major bleeding [ Time Frame: 3 years ]
Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.
Major bleeding [ Time Frame: 4 years ]
Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.

Secondary Outcome Measures :

Cerebrovascular events defined as Stroke [ Time Frame: 4 months ]
Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.
Cerebrovascular events defined as Stroke [ Time Frame: 8 months ]
Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.
Cerebrovascular events defined as Stroke [ Time Frame: 12 months ]
Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.
Cerebrovascular events defined as Stroke [ Time Frame: 16 months ]
Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.
Cerebrovascular events defined as Stroke [ Time Frame: 20 months ]
Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.
Cerebrovascular events defined as Stroke [ Time Frame: 24 months ]
Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.
Cerebrovascular events defined as Stroke [ Time Frame: 3 years ]
Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.
Cerebrovascular events defined as Stroke [ Time Frame: 4 years ]
Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.
Transient Ischemic Attacks (TIA) [ Time Frame: 4 months ]
Number of Transient Ischemic Attacks (TIA)
Transient Ischemic Attacks (TIA) [ Time Frame: 8 months ]
Number of Transient Ischemic Attacks (TIA)
Transient Ischemic Attacks (TIA) [ Time Frame: 12 months ]
Number of Transient Ischemic Attacks (TIA)
Transient Ischemic Attacks (TIA) [ Time Frame: 16 months ]
Number of Transient Ischemic Attacks (TIA)
Transient Ischemic Attacks (TIA) [ Time Frame: 20 months ]
Number of Transient Ischemic Attacks (TIA)
Transient Ischemic Attacks (TIA) [ Time Frame: 24 months ]
Number of Transient Ischemic Attacks (TIA)
Transient Ischemic Attacks (TIA) [ Time Frame: 3 years ]
Number of Transient Ischemic Attacks (TIA)
Transient Ischemic Attacks (TIA) [ Time Frame: 4 years ]
Number of Transient Ischemic Attacks (TIA)
Acute coronary syndromes [ Time Frame: 4 months ]
Number including unstable angina, STEMI, Non-STEMI
Acute coronary syndromes [ Time Frame: 8 months ]
Number including unstable angina, STEMI, Non-STEMI
Acute coronary syndromes [ Time Frame: 12 months ]
Number Including unstable angina, STEMI, Non-STEMI
Acute coronary syndromes [ Time Frame: 16 months ]
Number including unstable angina, STEMI, Non-STEMI
Acute coronary syndromes [ Time Frame: 20 months ]
Number including unstable angina, STEMI, Non-STEMI
Acute coronary syndromes [ Time Frame: 24 months ]
Number including Unstable angina, STEMI, Non-STEMI
Acute coronary syndromes [ Time Frame: 3 years ]
Number including unstable angina, STEMI, Non-STEMI
Acute coronary syndromes [ Time Frame: 4 years ]
Number including unstable angina, STEMI, Non-STEMI
Therapy persistence [ Time Frame: 4 months ]
Participant duration of time on therapy
Therapy persistence [ Time Frame: 8 months ]
Participant duration of time on therapy
Therapy persistence [ Time Frame: 12 months ]
Participant duration of time on therapy
Therapy persistence [ Time Frame: 16 months ]
Participant duration of time on therapy
Therapy persistence [ Time Frame: 20 months ]
Participant duration of time on therapy
Therapy persistence [ Time Frame: 24 months ]
Participant duration of time on therapy
Therapy persistence [ Time Frame: 3 years ]
Participant rate of discontinuation
Therapy persistence [ Time Frame: 4 years ]
Participant duration of time on therapy
Incidences of other clinical events [ Time Frame: 4 months ]
Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)
Incidences of other clinical events [ Time Frame: 8 months ]
Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)
Incidences of other clinical events [ Time Frame: 12 months ]
Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)
Incidences of other clinical events [ Time Frame: 16 months ]
Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)
Incidences of other clinical events [ Time Frame: 20 months ]
Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)
Incidences of other clinical events [ Time Frame: 24 months ]
Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)
Incidences of other clinical events [ Time Frame: 3 years ]
Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)
Incidences of other clinical events [ Time Frame: 4 years ]
Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)
Bleeding Events [ Time Frame: 4 months ]
Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event
Bleeding Events [ Time Frame: 8 months ]
Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event
Bleeding Events [ Time Frame: 12 months ]
Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event
Bleeding Events [ Time Frame: 16 months ]
Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event
Bleeding Events [ Time Frame: 20 months ]
Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event
Bleeding Events [ Time Frame: 24 months ]
Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event
Bleeding Events [ Time Frame: 3 years ]
Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event
Bleeding Events [ Time Frame: 4 years ]
Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event
Pulmonary Embolism [ Time Frame: 4 months ]
Number of participants with a Pulmonary Embolism
Pulmonary Embolism [ Time Frame: 8 months ]
Number of participants with a Pulmonary Embolism
Pulmonary Embolism [ Time Frame: 12 months ]
Number of participants with a Pulmonary Embolism
Pulmonary Embolism [ Time Frame: 16 months ]
Number of participants with a Pulmonary Embolism
Pulmonary Embolism [ Time Frame: 20 months ]
Number of participants with a Pulmonary Embolism
Pulmonary Embolism [ Time Frame: 24 months ]
Number of participants with a Pulmonary Embolism
Pulmonary Embolism [ Time Frame: 3 years ]
Number of participants with a Pulmonary Embolism
Pulmonary Embolism [ Time Frame: 4 years ]
Number of participants with a Pulmonary Embolism

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Male and female patients newly diagnosed with atrial fibrillation (AF) who are with at least one additional risk of stroke from 18 countries globally.

Criteria

Inclusion Criteria:

Prospective Cohort

Written informed consent
Age 18 years and older
New diagnosis of non-valvular atrial fibrillation (diagnosed within the last 6 weeks) with at least one additional risk factor for stroke and regardless of therapy.

Retrospective validation cohort

Written informed consent
Age 18 years and older
Diagnosis of non-valvular AF (diagnosed 6-24 months prior to enrolment) with at least one additional risk factor for stroke and regardless of therapy.

Exclusion criteria:

No further follow-up envisaged or possible within enrolling hospital or with associated family practitioner.
Patients with transient AF secondary to a reversible cause.
Patients recruited in controlled clinical trials.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01090362

Locations

Show 35 study locations

Layout table for location information

United States, Massachusetts
Prof. Samuel Goldhaber
Boston, Massachusetts, United States, 02115
Argentina
Dr Hector Luciardi, National Co-ordinating Investigator, National University of Tucuman
Tucumán, Argentina
Australia
Harry Gibbs, National Co-ordinating Investigator, The Alfred Hospital
Melbourne, Australia
Austria
Marianne Brodmann: National Co-ordinating Investigator, Medizinische Universität Graz
Graz, Austria
Belgium
Dr Frank Cools, National Co-ordinating Investigator, AZ Klina
Brasschaat, Belgium
Brazil
Dr Antonio Barretto, National Coordinating Investigator, Hospital Santa Marcelina,
São Paulo, Brazil
Canada
Prof Stuart Connolly and Dr John Eikelboom, National Coodinating Investigators, Mc Master University
Hamilton, Canada
Chile
Dr Ramon Corbalan, National Coordinating Investigator, Pontifica Universidad Catolica de Chile
Santiago, Chile
China
Prof Zin-Cheng, National Coordinating Investigator, Peking Union Medical College & Chinese Academy Medical Sciences People Hospital
Beijing, China
Czechia
Dr Petr Jansky, National Coordinating Investigator, Cardiovaskular Center, Motol Univesity Hospital
Prague, Czechia
Denmark
Prof Joern Dalsgaard Nielsen, National Coordinating Investigator, Bispebjerg & Frederiksberg Hospitals
Frederiksberg, Denmark
Egypt
Dr. Hany Ragy, National Coordinating Investigator, Hayat Hospital
Cairo, Egypt
Finland
Prof Pekka Raatikainen, National Coordinating Investigator, Univesrsity of Tampere
Tampere, Finland
France
Prof. Jean-Yues LeHeuzey, National Coordinating Investigator, Hopital Europeen Georges Pompidou
Paris, France
Germany
Prof Harald Darius, National oordinating Investigator, Vivantes Klinikum Neukölln
Berlin, Germany
Hungary
Dr Matyas Keltai, National Coordinating Investigator, Hungarian Institute of Cardiology
Budapest, Hungary
India
Dr Sawney, National Coordinating Investigator, Sir Ganga Ram Hospital, New Delhi
Bangalore, India
Italy
Profs Giancarlo Agnelli and Giuseppe Ambrosio, National Coordinating Investigators, University of Perugia
Perugia, Italy
Japan
Professor Yukihiro Koretsune, National Coordinating Investigator, Osaka National Hospital
Osaka, Japan
Korea, Republic of
Prof. Seil Oh, National Coordinating Investigator, National University Hospital
Seoul, Korea, Republic of
Mexico
Dr Carlos Jerjes Sanchez Diaz, National Coordinating Investigator,Tecnologico de Monterrey
Monterrey, Mexico
Netherlands
Professor Hugo ten Cate, National Coordinating Investigator, Cardiovascular Research Institute Maastricht
Maastricht, Netherlands
Norway
Professor Dan Atar, National Coordinating Investigator, Oslo University Hospital
Oslo, Norway
Poland
Prof Janina Stępińska, National Coordinating Investigator, Institute of Cardiology, Warsaw
Warsaw, Poland
Russian Federation
Professor Elizaveta Panchenko, National Coordinating Investigator, Cardiology Research and Production Center
Moscow, Russian Federation
Singapore
Dr Toon Wei Lim, National Coordinating Investigator, National University Hospital
Singapore, Singapore
South Africa
Prof. Barry Jacobson, National Coordinating Investigator, University of the Witwatersrand
Johannesburg, South Africa
Spain
Dr Xavier Vinolas, National Coordinating Investigator, Hospital Santa Creu y San Pau
Barcelona, Spain
Sweden
Dr Marten Rosenqvist, National Coordinating Investigator, Karolinska Institute
Stockholm, Sweden
Switzerland
Dr Jan Steffel, National Coordinating Investigator, University Hospital
Zurich, Switzerland
Thailand
Prof. Pantep Angchaisuksiri, National Coordinating Investigator, Ramathibodi Hospital, Mahidol University
Bangkok, Thailand
Turkey
Professor Ali Oto, National Coordinating Investigator, Memorial Ankara Hospital
Ankara, Turkey
Ukraine
Prof. Alexandr Parkhomenko, National Coordinating Investigator, Strazhesko Institute of Cardiology
Kiev, Ukraine
United Arab Emirates
Prof. Wael Al Mahmeed, National Coordinating Investigator, SKMC Cardiac Siences
Abu Dhabi, United Arab Emirates
United Kingdom
Prof. David Fitzmaurice, National Coordinating Investigator, University of Warwick
Coventry, United Kingdom

Sponsors and Collaborators

Thrombosis Research Institute

Bayer

University of Birmingham

Brigham and Women's Hospital

Quintiles, Inc.

Advanced Drug and Device Services SAS

Apothecaries Clinical Research

Investigators

Layout table for investigator information

Study Director:	Ajay K Kakkar	Thrombosis Research Institute, London, UK

More Information

Additional Information:

Sponsor's website This link exits the ClinicalTrials.gov site

Publications of Results:

Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Turpie AG, van Eickels M, Misselwitz F, Rushton-Smith S, Kayani G, Wilkinson P, Verheugt FW; GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013 May 21;8(5):e63479. doi: 10.1371/journal.pone.0063479. Print 2013.

Other Publications:

Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Verheugt FW, Jamal W, Misselwitz F, Rushton-Smith S, Turpie AG. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012 Jan;163(1):13-19.e1. doi: 10.1016/j.ahj.2011.09.011. Epub 2011 Nov 20.

Apenteng PN, Murray ET, Holder R, Hobbs FD, Fitzmaurice DA; UK GARFIELD Investigators and GARFIELD Steering Committee. An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. BMC Cardiovasc Disord. 2013 Apr 23;13:31. doi: 10.1186/1471-2261-13-31.

Aalbers J. GARFIELD: a window on the real-life treatment of atrial fibrillation - South Africa joins the GARFIELD registry. Cardiovasc J Afr. 2012 Oct;23(9):528.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Pope MK, Atar D, Svilaas A, Hole T, Nielsen JD, Hintze U, Crisby M, Raatikainen P, Airaksinen KEJ, Virdone S, Pieper K, Kayani G, Le Heuzey JY, Steffel J, Stepinska J, Bassand JP, Camm AJ; GARFIELD-AF Investigators. Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry. Ann Med. 2021 Dec;53(1):485-494. doi: 10.1080/07853890.2021.1893897.

Sayin BY, Al Mahmeed W, Ragy HI, Elbahry A, Virdone S, Kakkar AK, Ersanlı M, Oto A. Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study. Adv Ther. 2021 May;38(5):2391-2405. doi: 10.1007/s12325-021-01670-5. Epub 2021 Mar 27.

Gibbs H, Freedman B, Rosenqvist M, Virdone S, Mahmeed WA, Ambrosio G, Camm AJ, Jacobson B, Jerjes-Sanchez C, Kayani G, Oto A, Panchenko E, Ragy H, Kakkar AK; GARFIELD-AF Investigators. Clinical Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation Presentations in GARFIELD-AF: Implications for AF Screening. Am J Med. 2021 Jul;134(7):893-901.e11. doi: 10.1016/j.amjmed.2021.01.017. Epub 2021 Feb 16.

Bassand JP, Virdone S, Badoz M, Verheugt FWA, Camm AJ, Cools F, Fox KAA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Kakkar AK. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv. 2021 Feb 23;5(4):1081-1091. doi: 10.1182/bloodadvances.2020003560.

Camm AJ, Fox KAA, Virdone S, Bassand JP, Fitzmaurice DA, Berchuck SI, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Cappato R, Kakkar AK; GARFIELD-AF investigators. Comparative effectiveness of oral anticoagulants in everyday practice. Heart. 2021 Feb 16. pii: heartjnl-2020-318420. doi: 10.1136/heartjnl-2020-318420. [Epub ahead of print]

Camm AJ, Cools F, Virdone S, Bassand JP, Fitzmaurice DA, Arthur Fox KA, Goldhaber SZ, Goto S, Haas S, Mantovani LG, Kayani G, Grierson Turpie AG, Antoon Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. J Am Coll Cardiol. 2020 Sep 22;76(12):1425-1436. doi: 10.1016/j.jacc.2020.07.045.

Bassand JP, Apenteng PN, Atar D, Camm AJ, Cools F, Corbalan R, Fitzmaurice DA, Fox KA, Goto S, Haas S, Hacke W, Jerjes-Sanchez C, Koretsune Y, Heuzey JL, Sawhney JP, Oh S, Stępińska J, Cate VT, Verheugt FW, Kayani G, Pieper KS, Kakkar AK, Garfield-Af Investigators FT. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiol. 2021 Jan;17(1):19-38. doi: 10.2217/fca-2020-0014. Epub 2020 Jul 22.

Hacke W, Bassand JP, Virdone S, Camm AJ, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AG, van Eickels M, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry. Int J Stroke. 2020 Apr;15(3):308-317. doi: 10.1177/1747493019891516. Epub 2019 Dec 17.

Atar D, Berge E, Le Heuzey JY, Virdone S, Camm AJ, Steffel J, Gibbs H, Goldhaber SZ, Goto S, Kayani G, Misselwitz F, Stepinska J, Turpie AGG, Bassand JP, Kakkar AK; GARFIELD-AF Investigators. The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events. Europace. 2020 Feb 1;22(2):195-204. doi: 10.1093/europace/euz292.

Verheugt FWA, Ambrosio G, Atar D, Bassand JP, Camm AJ, Costabel JP, Fitzmaurice DA, Illingworth L, Goldhaber SZ, Goto S, Haas S, Jansky P, Kayani G, Stepinska J, Turpie AGG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. Am J Med. 2019 Dec;132(12):1431-1440.e7. doi: 10.1016/j.amjmed.2019.06.008. Epub 2019 Jul 12.

Haas S, Camm AJ, Bassand JP, Angchaisuksiri P, Cools F, Corbalan R, Gibbs H, Jacobson B, Koretsune Y, Mantovani LG, Misselwitz F, Panchenko E, Ragy HI, Stepinska J, Turpie AG, Sawhney JP, Steffel J, Lim TW, Pieper KS, Virdone S, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. Am Heart J. 2019 Jul;213:35-46. doi: 10.1016/j.ahj.2019.03.013. Epub 2019 Apr 11.

Corbalan R, Bassand JP, Illingworth L, Ambrosio G, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry. JAMA Cardiol. 2019 Jun 1;4(6):526-548. doi: 10.1001/jamacardio.2018.4729.

Jerjes-Sanchez C, Corbalan R, Barretto ACP, Luciardi HL, Allu J, Illingworth L, Pieper KS, Kayani G; GARFIELD-AF Investigators. Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry. Clin Cardiol. 2019 May;42(5):553-560. doi: 10.1002/clc.23176. Epub 2019 Apr 9.

Goto S, Angchaisuksiri P, Bassand JP, Camm AJ, Dominguez H, Illingworth L, Gibbs H, Goldhaber SZ, Goto S, Jing ZC, Haas S, Kayani G, Koretsune Y, Lim TW, Oh S, Sawhney JPS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. J Am Heart Assoc. 2019 Feb 5;8(3):e010510. doi: 10.1161/JAHA.118.010510.

Bassand JP, Virdone S, Goldhaber SZ, Camm AJ, Fitzmaurice DA, Fox KAA, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK. Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. Circulation. 2019 Feb 5;139(6):787-798. doi: 10.1161/CIRCULATIONAHA.118.035012.

Sawhney JP, Kothiwale VA, Bisne V, Durgaprasad R, Jadhav P, Chopda M, Vanajakshamma V, Meena R, Vijayaraghavan G, Chawla K, Allu J, Pieper KS, John Camm A, Kakkar AK; GARFIELD-AF Investigators. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart J. 2018 Nov - Dec;70(6):828-835. doi: 10.1016/j.ihj.2018.09.001. Epub 2018 Sep 12.

Cools F, Wollaert B, Vervoort G, Verstraete S, Voet J, Hermans K, Heyse A, De Wolf A, Hollanders G, Boussy T, Anné W, Vercammen J, Faes D, Beutels M, Mairesse G, Purnode P, Blankoff I, Vandergoten P, Capiau L, Allu J, Bassand JP, Kayani G; GARFIELD-AF Investigators. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. Acta Cardiol. 2019 Aug;74(4):309-318. doi: 10.1080/00015385.2018.1494089. Epub 2018 Oct 27.

Bassand JP, Accetta G, Al Mahmeed W, Corbalan R, Eikelboom J, Fitzmaurice DA, Fox KAA, Gao H, Goldhaber SZ, Goto S, Haas S, Kayani G, Pieper K, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS One. 2018 Jan 25;13(1):e0191592. doi: 10.1371/journal.pone.0191592. eCollection 2018.

Apenteng PN, Gao H, Hobbs FR, Fitzmaurice DA; UK GARFIELD-AF Investigators and GARFIELD-AF Steering Committee. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry. BMJ Open. 2018 Jan 13;8(1):e018905. doi: 10.1136/bmjopen-2017-018905.

Verheugt FWA, Gao H, Al Mahmeed W, Ambrosio G, Angchaisuksiri P, Atar D, Bassand JP, Camm AJ, Cools F, Eikelboom J, Kayani G, Lim TW, Misselwitz F, Pieper KS, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. Eur Heart J. 2018 Feb 7;39(6):464-473. doi: 10.1093/eurheartj/ehx730.

Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Oto A, Mantovani LG, Misselwitz F, Piccini JP, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017 Dec 21;7(12):e017157. doi: 10.1136/bmjopen-2017-017157.

Fox KAA, Accetta G, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Kayani G, Kakkar AK; GARFIELD-AF Investigators. Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). Eur Heart J Qual Care Clin Outcomes. 2018 Jan 1;4(1):27-35. doi: 10.1093/ehjqcco/qcx030.

Camm AJ, Accetta G, Al Mahmeed W, Ambrosio G, Goldhaber SZ, Haas S, Jansky P, Kayani G, Misselwitz F, Oh S, Oto A, Raatikainen P, Steffel J, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open. 2017 Mar 6;7(3):e014579. doi: 10.1136/bmjopen-2016-014579.

Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, Corbalan R, Darius H, Fitzmaurice DA, Goldhaber SZ, Goto S, Jacobson B, Kayani G, Mantovani LG, Misselwitz F, Pieper K, Schellong SM, Stepinska J, Turpie AG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS One. 2016 Oct 28;11(10):e0164076. doi: 10.1371/journal.pone.0164076. eCollection 2016.

Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y, Mantovani LG, Misselwitz F, Oh S, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017 Feb 15;103(4):307-314. doi: 10.1136/heartjnl-2016-309832. Epub 2016 Sep 19.

Oh S, Goto S, Accetta G, Angchaisuksiri P, Camm AJ, Cools F, Haas S, Kayani G, Koretsune Y, Lim TW, Misselwitz F, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. Int J Cardiol. 2016 Nov 15;223:543-547. doi: 10.1016/j.ijcard.2016.08.236. Epub 2016 Aug 13.

Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Ten Cate H, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016 Oct 7;37(38):2882-2889. Epub 2016 Jun 29.

Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Janský P, Al Mahmeed W, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK; GARFIELD-AF Investigators. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2 Suppl 1):S12-20. doi: 10.1161/CIRCOUTCOMES.114.001556. Epub 2015 Feb 24.

Layout table for additonal information

Responsible Party:	Thrombosis Research Institute
ClinicalTrials.gov Identifier:	NCT01090362
Other Study ID Numbers:	TRI08888
First Posted:	March 19, 2010 Key Record Dates
Last Update Posted:	April 28, 2021
Last Verified:	April 2021

Keywords provided by Thrombosis Research Institute:


Atrial fibrillation Anticoagulation Stroke Stroke prevention Health Economics

Additional relevant MeSH terms:

Layout table for MeSH terms

Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes

To Top